Figure 2.

Macrophage‐selective uptake of DNDA. A) Quantitative MFI analysis of Cy5‐labeled DNDA uptake in CT26 and RAW264.7 cells. Data are shown as Mean ± SD (n = 3), and statistical significance was calculated via a two‐tailed unpaired t‐test, ^*** p < 0.001. B) The cellular uptake level of Cy5‐labeled DNDA in CT26 cocultured with RAW264.7 in indicated tumor cell/macrophage (T/M) ratios. Data are shown as Mean ± SD (n = 3), and statistical significance was calculated via two‐way ANOVA with Sidak's post hoc test, ^*** p < 0.001. C) Percentage of Cy5⁺ tumor cells (gated on L/D⁻ Cy5⁺ GFP⁺ cells) and Cy5⁺ macrophages (gated on L/D⁻ Cy5⁺ CD45⁺ CD11b⁺ F4/80⁺ cells) in DNDA‐Cy5⁺ cells after injected with Cy5‐labeled DNDA in MC38‐GFP tumor‐bearing mice. Data are shown as Mean ± SD (n = 5), and statistical significance was calculated via two‐tailed unpaired t‐test, ^*** p < 0.001. D) Representative flow cytometric plots of Cy5⁺ GFP⁺ tumor cells and Cy5⁺ macrophages in tumors. E,F) Quantitative Cy5 MFI analysis in tumor cells and macrophages at 12 h post intratumoral injection of Cy5‐labeled DNDA. Data are shown as the Mean ± SD (n = 5), and statistical significance was calculated via a two‐tailed unpaired t‐test, ^*** p < 0.001.